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José E. Mesonero‡, Sergio M. Gloor, and Giorgio Semenza§¶
From the Department of Biochemistry, Swiss Federal Institute of Technology, ETH Zentrum, CH-8092 Zurich,
Switzerland and the §Dipartimento di Chimica e Biochimica Medica, Università di Milano, I-20133 Milano, Italy
Human lactase-phlorizin hydrolase (human-LPH) is
synthesized as a large precursor (prepro-LPH), then
cleaved to a pro-LPH of 220 kDa which is further cut to
a “mature-like LPH” of a size close to that of mature
LPH, i.e. about 150 kDa (in the processing of rabbit
pro-LPH the intermediate has a mass of approximately
180 kDa). By coexpression of human prepro-LPH with
furin in COS-7 cells we show that furin generates a ma-
ture-like LPH. Radioactive amino acid sequence analy-
sis reveals that furin recognizes the motif R-T-P-R832, a
protein convertase consensus, to generate a NH2 termi-
nus located 36 amino acids upstream of the NH2 termi-
nal found in vivo at Ala869. This intermediate is ulti-
mately cleaved to the mature LPH form by other
proteases including the pancreatic ones. These data
demonstrate that human pro-LPH, like the rabbit en-
zyme, is processed to the mature enzyme by furin or
furin-like enzymes through at least an intermediate
form that has, however, an apparent mass close to that
of the mature enzyme.
Small intestinal lactase-phlorizin hydrolase (LPH,1 EC
3.2.1.23–62), hydrolyzing lactose and other b-glycosides, is an
integral membrane glycoprotein located in the intestinal
brush-border membrane. Human LPH is synthesized as a large
precursor (prepro-LPH) of 1927 amino acid residues, beginning
with the leading sequence followed by four homologous regions
(I–IV) and then by a membrane-spanning domain (1, 2) and a
cytosolic COOH-terminal sequence (3). This precursor is glyco-
sylated and subjected to proteolytic processing events on its
way from the endoplasmic reticulum (ER) to the brush-border
membrane. Mature LPH consists of somewhat more than the
COOH-terminal half portion of prepro-LPH, i.e. two of the four
homologous regions (regions III and IV) plus the transmem-
brane and the cytosolic segments.
The first protease acting on prepro-LPH is signal peptidase
in the ER, which was predicted (1) and found in transfected
MDCK cells (4) to split the human prepro enzyme between
positions 19 and 20. Subsequently, enterocytes process pro-
LPH to a “mature-like” LPH apparently in one step (5–8),
whereas in the rabbit the formation of a 180-kDa intermediate
is clearly evident (9, 10). Note that we indicate as mature-like
LPHs those lactase forms that have a molecular size similar to,
but have not been demonstrated to have an amino acid se-
quence identical to that of mature brush-border LPH.
Endoproteolytic cleavages at sites comprising the sequence
motifs -R-R- or K/R-X-X-R- participate in the post-translational
processing of many proteins. The subtilisin-related proprotein
convertases (PCs) are a family of calcium-dependent serine
endoproteases. These enzymes share between 50 and 74%
amino acid sequence identity in the subtilisin-like catalytic
domain (for reviews on their substrate consensus motifs, see,
e.g., Refs. 11 and 12). Two main subsets of enzymes can be
distinguished. The first includes convertases such as PC2 (13)
and PC1/3 (14), which are expressed mainly in neuroendocrine
tissues and brain, in which they are located in secretory vesi-
cles. These enzymes play a key role in allowing the formation of
active hormones or neuropeptides from biologically inactive
precursors. The second subset of convertases, which includes
furin (15, 16), PACE4 (17), and PC5/6 (18, 19), shows wide
tissue expression in the body. PACE4, PC5/6B, and especially
furin have been shown to be involved in precursor processing of
constitutively secreted proteins such as growth factors and
their receptors (20, 21) and in cleavage of viral proteins (22).
mRNAs of furin, PC1/3, and PC6A have been detected in rabbit
enterocytes by in situ hybridization (23).
Recent reports have suggested that processing of human pro-
LPH to mature LPH in the intestine occurs in more than one step
(4, 24). The detailed mechanism, however, is not known. Because
the pro region of human LPH contains several potential cleavage
sites for subtilisin-like proteases (one site occurs upstream of, but
not immediately preceding the NH2 terminus of mature, brush-
border LPH), we examined their potential to process human
pro-LPH. We have now identified furin as a likely candidate
involved in the first step of the maturation of human pro-LPH.
Furin or furin-like PC(s) can generate a mature-like LPH that is
36 amino acids longer than mature LPH. Further proteolytic
processing of this mature-like LPH form of human lactase to
generate the final mature LPH form includes the eventual,
albeit limited, action of pancreatic proteases (e.g. trypsin).
EXPERIMENTAL PROCEDURES
Materials—All chemicals were of the highest possible purity and
were purchased from Fluka (Buchs, Switzerland) unless otherwise in-
dicated. pSCTmLPH (human prepro-LPH (25)) was prepared in our
laboratory. The cDNA coding for mouse furin, pSCTmfurin (26), was
provided by Dr. K. Nakayama, University of Tsukuba, Japan, and
subcloned into the vector pSCT Gal-X-556 (27).
Mutagenesis and Construction of cDNA Clones—Three double muta-
tions were generated at basic residues located upstream of the NH2
terminus of mature lactase: R829T/R832T, K853T/R854T, and K866T/
R868T (see Fig. 4). Prepro-LPH cDNA was subcloned from the plasmid
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pSCTmLPH (human prepro-LPH (25)) into the vector pGEM-2 (Pro-
mega, Switzerland). A 3.5-kilobase fragment was deleted with PvuII
and the resulting plasmid used for site-directed mutagenesis using the
Unique Site Elimination mutagenesis kit (Pharmacia, Switzerland).
The mutagenesis reactions were performed with the following mutant
sense primers (the nucleotides causing the mutation are underlined):
LPH R829T/R832T, 59-GC AGC AAG TCA ACG ACT CCC ACG AAA
TCT GCC-39; LPH K853T/R854T, 59-CC AAG GGG GCA ACA ACA CTG
CTA CCA CC-39; LPH K866T/R868T, 59-C CTC CCC TCC ACA GTC
ACA GCC TTC ACT TTT CC-39. The mutations were confirmed by DNA
sequencing using the following sense primer: 59-CCT TCT GGT TAC
AGC CAG CGG-39. After mutation, the 3.5-kilobase PvuII fragment
was reinserted. The final expression vectors, pcDNA I/Amp LPH
R829T/R832T, pcDNA I/Amp LPH K853T/R854T, pcDNA I/Amp LPH
K866T/R868T, and pcDNA I/Amp LPH wt (wild type), were constructed
by cloning the mutated and wt LPH cDNA into the EcoRI site of pcDNA
I/Amp (Invitrogen, Switzerland).
Transient Transfection of Cells—COS-7 cells, cultured in Dulbecco’s
modified Eagle’s medium and 10% fetal calf serum (Life Technologies,
Switzerland), were transiently transfected as described by Chen and
Okayama (28). One day before transfection, the cells were seeded into
six-well plates, to reach approximately 80% confluence the next day.
During the last 30 min before transfection, the cells were incubated in
1.5 ml of fresh Dulbecco’s modified Eagle’s medium and 10% fetal calf
serum at 37 °C and 3.5% CO2. The calcium phosphate-DNA mixture
was prepared by mixing 5 mg of plasmid DNA with 100 ml of 250 mM
CaCl2 and 100 ml of 2 3 BBS (50 mM BES, 280 mM NaCl, 1.5 mM
Na2HPO4, pH adjusted with NaOH to exactly 6.95) and incubating for
15 min at room temperature. 150 ml of this mixture was then added
slowly to the cells, and incubation was continued for 24 h at 37 °C and
3.5% CO2. The following day, the cells were washed twice with phos-
phate-buffered saline (PBS), refed 2 ml of fresh medium, and incubated
for 24 h at 37 °C and 5% CO2.
Biosynthetic Labeling and Immunoprecipitation—For metabolic la-
beling studies, the cells were washed with minimal essential medium
(methionine-free) 48 h after transfection and then incubated in 2 ml of
methionine-free labeling medium (minimal essential medium supple-
mented with 10% dialyzed fetal calf serum) for 1 h at 37 °C and 5% CO2.
After depletion of methionine, the cells were pulse labeled in 1 ml of
labeling medium containing 25 mCi of [35S]methionine (Amersham,
Switzerland, specific activity . 1,000 Ci/mmol) for the time period
indicated. The cells were washed twice with PBS and chased in Dul-
becco’s modified Eagle’s medium and 10% fetal calf serum supple-
mented with 10 mM methionine. In some experiments, brefeldin A
(BFA) was added to all media at a concentration of 5 mg/ml. The furin
inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (29) was
added to all media needed at a final concentration of 100 mM. The
labeled cells were collected and solubilized in 400 ml of lysis buffer (25
mM Tris-HCl, pH 8.0, 50 mM NaCl, 1% deoxycholate, 1% Nonidet P-40,
0.01 volume of 100 mM phenylmethylsulfonyl fluoride, 0.01 volume of
inhibitor mixture (0.25 mg/ml pepstatin, 0.06 mg/ml aprotinin, 1.1
mg/ml leupeptin, 4.7 mg/ml benzamidine, 0.24 mg/ml bestatin, 0.3 mg/ml
E-64, and 38.3 mg/ml o-phenanthroline). Immunoprecipitations, using a
monoclonal mouse anti-human LPH antibody (30), were performed as
described by Lottaz et al. (31). In some experiments equal volumes of cell
lysates were treated with 50 mg of trypsin for different time intervals at
37 °C, and then the reaction was stopped with phenylmethylsulfonyl
fluoride, the inhibitor mixture, and 200 mg of soybean trypsin inhibitor.
The samples were then processed further for immunoprecipitation.
N-Glycosidase F Treatment—Immunoprecipitated proteins were
eluted from Sepharose beads by boiling in 30 ml of 100 mM sodium
acetate, pH 5.5, containing 0.2% SDS for 4 min. Then 3 ml of 10 3 Glyco
F buffer (500 mM Tris-HCl, pH 6.8, 200 mM b-mercaptoethanol, 1%
SDS, 5% Nonidet P40) and 200 milliunits of peptide-N-glycosidase F
(PNGase F, Boehringer, Switzerland) were added, and the mixture was
incubated for 16 h at 37 °C.
SDS-PAGE—Samples (immunoprecipitates and proteins subjected
to PNGase F treatment) were analyzed by SDS-PAGE in 5% acrylamide
gels according to Laemmli (32). The gels were stained and fixed with
Coomassie Blue R-250 in 10% ethanol and 5% acetic acid, destained,
and treated with Amplify (Amersham, Switzerland) for 30 min, dried,
and then exposed to Fuji RX medical x-ray films at 280 °C. The per-
centage of processed human LPH was obtained by quantifying the
radioactivity in the dried gels with a PhosphoImager scanner using
Imagequant 3.2 software (both from Molecular Dynamics).
Immunofluorescence—Transfected cells grown on glass coverslips
were fixed for 30 min with 3% paraformaldehyde in PBS, treated for 15
min with 0.1 M glycine in PBS, and permeabilized or not for 5 min with
0.25% Triton X-100 in PBS. LPH wt and its mutants were detected with
the monoclonal anti-human LPH antibody and fluorescein isothiocya-
nate-conjugated goat anti-mouse secondary antibody (1:100, Tago,
Switzerland).
Measurement of Lactase Activity and Protein Determination—COS-7
cells transfected with LPH wt or LPH mutants were detached with a
rubber policeman and collected in cold PBS. The cells were disrupted
with a conical grinding pestle and sonicated (15 s, 60 watts). Lactase
activity was determined as described by Wacker et al. (2). Briefly, cell
homogenates were incubated at 37 °C for 1 h in 33 mM sodium maleate
buffer, pH 6.0, using 33 mM lactose as substrate. After boiling for 2 min
the liberated D-glucose was determined at 365 nm with D-glucose de-
hydrogenase (Merck). Protein concentrations were determined by the
method of Bradford (33).
Amino Acid Sequence Analysis of Pro-LPH and Mature-like LPH
Forms—Pro-LPH and mature-like LPH were immunopurified from
COS-7 transfected cells, separated by gel electrophoresis, and blotted
onto a polyvinylidene difluoride membrane. The membrane was washed
and stained in 0.1% Coomassie Blue R-250 in 50% methanol. Individual
protein bands were cut from the membrane. The NH2-terminal amino
acid sequence of a portion of each band was determined by automated
Edman degradation using an Applied Biosystems 470 gas phase Se-
quencer. When radioactive amino acid sequencing was performed,
COS-7 cells cotransfected with prepro-LPH and furin cDNAs were
labeled with [3H]phenylalanine for 1 h and chased for 16 h. The immu-
noprecipitated proteins were separated by SDS-PAGE, then radioactive
bands were excised from the polyvinylidene difluoride membrane and
used directly for protein sequence determination. Radioactivity in each
cycle was determined by collecting the anilinothiazolinone amino acid
derivatives and counting in a Beckman LS1801 scintillation counter.
RESULTS
Processing of Human Prepro-LPH and Pro-LPH in Trans-
fected COS-7 Cells—Human prepro-LPH undergoes a number
of incompletely described proteolytic cleavage events in the
constitutive secretion pathway in vivo. To study the processing
of human prepro-LPH in detail we used COS-7 cells as a model.
This cell line was used successfully in our laboratory to study the
processing of rabbit lactase (23). Fig. 1A shows that the lactase
precursor, immunopurified from transiently transfected COS-7
cells, is processed to a 150-kDa mature or mature-like protein.
This processing, however, takes place far more slowly than in
enterocytes. COS-7 cells need almost 3 days to process pro-LPH
completely to the 150-kDa mature or mature-like protein.
To investigate the processing in detail, we first examined
whether cleavage of prepro-LPH by signal peptidase in COS-7
FIG. 1. Lactase production in COS-7 cells. Panel A, biosynthesis
and post-translational processsing of pro-LPH expressed in COS-7 cells.
The cells were radiolabeled for 2 h followed by a chase for the time periods
indicated. After electrophoresis the dried gel was exposed for autoradiog-
raphy. 210 kDa 5 pro-LPH (high mannose form); 220 kDa 5 pro-LPH
(complex-glycosylated form); 150 5 mature-like LPH. Panel B, NH2-ter-
minal amino acid sequence (residues 20–27) of pro-LPH produced in
transfected COS-7 cells determined by direct amino acid sequencing.
























cells occurred at the same position as expected in enterocytes
(1) and as found in MDCK cells transfected with prepro-LPH
cDNA (4). NH2-terminal amino acid sequence determination of
immunopurified pro-LPH confirms that the cleavage takes
place after Gly19, i.e. where predicted for human prepro-LPH
(1) (Fig. 1B). However, for the further processing of pro-LPH to
mature or mature-like LPH, we failed to obtain an unambiguous
NH2-terminal amino acid sequence of this LPH form (approxi-
mately 150 kDa) slowly generated in COS-7 cells, suggesting that
pro-LPH is cleaved at more than one site in COS-7 cells.
Generation of Mature-like LPH Form in COS-7 Cells Ex-
pressing Furin—We have shown previously that predomi-
nantly furin, PC1/3, and/or PC6A are implicated in the proc-
essing of rabbit pro-LPH to generate the 180-kDa intermediate
form (23). We therefore investigated whether furin generates
human mature-like LPH. Furin is localized mainly in the
trans-Golgi network with ubiquitous tissue distribution (12).
Furthermore, it can translocate between the cell surface and
the trans-Golgi network (34, 35), a behavior that is in agree-
ment with its proposed role in multiple processing events.
To examine the potential of furin to cleave human pro-LPH
in detail, COS-7 cells were transfected with the full-length
cDNA of prepro-LPH together with the cDNA of furin. Fig. 2A
shows that furin is able to increase the amount of protein
referred to as mature-like LPH approximately 3-fold after 5 h
of chase. The apparent molecular mass is very similar to the
mass of mature-like lactase generated by endogenous proteases
in COS-7 cells (150 kDa). This is more clearly visible after
deglycosylation with PNGase F (Fig. 2B). Processing is blocked
by BFA (Fig. 2A), which interrupts transport from the ER to the
Golgi. Processing of pro-LPH in the small intestine is known to
take place in the trans-Golgi network or in a later compartment
(31, 36, 37), where furin is also known to be located.
The enhanced processing of pro-LPH by coexpressed furin is
inhibited by the membrane-permeant specific inhibitor of furin
decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (29) when added
to the medium during the pulse-chase period (Fig. 2C). This
inhibitor is not able to inhibit processing of lactase by COS-7 cell
endogenous proteases (although there is a reduction in the
amount of immunoprecipitated LPH forms, the inhibitor does not
alter the ratio between the 220-kDa pro-LPH and the 150-kDa
mature-like form). The cleavage of human pro-LPH in non-furin-
transfected COS-7 cells must thus be caused by other proteases.
Determination of NH2-terminal Sequence of the Intracellular
Mature-like LPH Generated by Furin—The results described in
the preceding paragraph show that overexpressed furin ele-
vates the split of pro-LPH to a mature-like protein in COS-7
cells. At least two furin motifs are present in human pro-LPH
shortly upstream of the mature NH2 terminus (i.e. at Arg
832
and Lys-Arg854, Fig. 3A). To identify the cleavage site used by
furin, COS-7 cells, cotransfected with prepro-LPH and furin
cDNA, were labeled with [3H]phenylalanine. The lactase forms
were immunoprecipitated, and mature-like lactases were sub-
jected to radioactive amino acid sequencing. The results (Fig.
3B) show that human pro-LPH is cleaved by furin after the
motif R-T-P-R832 (Fig. 3A) to generate a NH2 terminus starting
at Lys833. This protein is 36 amino acids longer than the native,
mature LPH found in the brush-border membrane (NH2 termi-
nus, Ala869) (1, 38).
Expression of Prepro-LPH Wild Type and Mutants—To pro-
vide further experimental evidence for the cleavage of pro-LPH
by furin, we altered the furin motif R-T-P-R by site-directed
mutagenesis (mutant pro-LPH R829T/R832T) and generated
two additional mutants: pro-LPH K853T/R854T (a dibasic site
located between the former and the final NH2 terminus) and
pro-LPH K866T/R868T (thus abolishing the K-V-R motif just in
front of the native NH2 terminus of mature LPH) (Fig. 4A). All
constructs as well as wt prepro-LPH were expressed in COS-7
cells. The cells were labeled with [35S]methionine for 1 h and
chased for 6 h. Immunoprecipitation of LPH wt with the anti-
body against the mature lactase reveals 210/220-kDa species
(the range of sizes of pro-LPH, high mannose and complex
glycosylated, respectively) and a weak (10% of total) 150-kDa
protein (approximately the size of mature LPH) (Fig. 4B). Im-
munoprecipitations of lactase mutants K853T/R854T and
K866T/R868T showed a pattern similar to that of lactase wt. In
contrast, immunoprecipitation of mutant pro-LPH R829T/
R832T revealed only one polypeptide with an apparent molec-
ular mass of 210 kDa which corresponded to the size of the high
mannose form (Fig. 4B). In the presence of cotransfected furin
we could again observe the furin-mediated enhanced process-
ing of wt pro-LPH as well as the enhanced processing of the
mutants K853T/R854T and K866T/R868T. However, in the
presence of coexpressed furin the mutant R829T/R832T is not
processed (Fig. 4B). Similar results were obtained with LoVo
and Ltk2 cells (data not shown).
FIG. 2. Analysis of endoproteolytic processing of human pro-LPH by furin. Panel A, COS-7 cells were transiently transfected either with
cDNA coding for human prepro-LPH alone or with cDNAs encoding furin and human prepro-LPH. The cells were metabolically labeled for 1 h and
chased for 5 h. BFA was used at a concentration of 5 mg/ml. mLPH, mature-like LPH. Panel B, COS-7 cells were transiently transfected either with
cDNA coding for human prepro-LPH or prepro-LPH together with cDNA coding for furin (chase time: 7 h). After immunoprecipitation the samples
were divided into two aliquots, one of which was treated with PNGase F before further processing. Panel C, COS-7 cells were transiently
transfected either with cDNA coding for human prepro-LPH or prepro-LPH together with cDNA coding for furin. The cells were metabolically
labeled for 1 h and chased for 7 h. The furin inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (furin inh.) was used at a concentration of
100 mM in the medium, during both pulse and chase.
























To examine the fate of this mutant R829T/R832T two param-
eters were studied: lactase enzymatic activity and cellular lo-
calization of this mutant. Fig. 4C (white bars) shows that lac-
tase activities of wt and the mutant proteins K853T/R854T and
K866T/R868T are clearly measurable (although the activity of
mutant K866T/R868T is somewhat lower). Mutant R829T/
R832T, in contrast, does not display detectable lactase activity.
Similar results were obtained in the presence of furin (Fig. 4C,
black bars). Because the enzymatic activity of pro-LPH is
known to be the same as that of mature LPH (39), the absence
of activity cannot simply be attributed to incomplete processing
of the pro-LPH mutant R829T/R832T. We tested whether mu-
tant R829T/R832T had reached the plasma membrane. COS-7
cells were transfected with wt or mutant cDNAs of prepro-
LPH. 48 h later, the cells were fixed and either permeabilized
with Triton X-100 or not permeabilized. Indirect immunofluo-
rescence was used to localize the lactase forms. Pro-LPH wt (a)
and mutants K853T/R854T (c) and K866T/R868T (d) are found
on the cell surface and also in intracellular compartments
(probably the ER and Golgi) (Fig. 5). Mutant R829T/R832T (b),
however, is detectable only after cell permeabilization and is
localized around the nucleus, i.e. it is retained intracellularly.
This observation is in agreement with the result shown in Fig.
4B for this mutation, where only the 210-kDa precursor, indic-
ative of high mannose pro-LPH, was expressed. The same
immunolocalization of pro-LPH wt and mutants was found in
cells cotransfected with furin (data not shown).
Further Processing of Mature-like LPH —It is known that
the treatment of pro-LPH molecules with trypsin alone gener-
ates a lactase with an apparent molecular mass similar to that
of brush-border mature LPH (39). Thus, it appears likely that
subsequent cleavage of human mature-like LPH by trypsin
leads to the generation of the “mature” enzyme in vivo. To
provide evidence for this assumption, we incubated cell ex-
tracts from COS-7 cotransfected with or without furin with
trypsin and analyzed the proteins by SDS-PAGE before and
after deglycosylation with PNGase F (Fig. 6). Deglycosylated
mature-like LPH treated with trypsin has an apparent molec-
ular mass of 120 kDa (corresponding to the calculated mass of
120,993 Da of mature human intestinal lactase). Deglycosy-
lated mature-like LPH not treated with trypsin has an appar-
ent molecular mass of approximately 124 kDa. This small shift in
the molecular mass of mature-like LPH produced by COS-7 cells
is independent of the presence or absence of overexpressed furin,
indicating again that endogenous COS-7 proteases cleave pro-
LPH very close to or at the furin motif around Arg832.
These results suggest that the brush-border mature LPH is
most probably produced by a multistep processing involving,
e.g. furin, perhaps more PC(s), aminopeptidases, granzyme A
(52), and/or pancreatic proteases (e.g. trypsin).
DISCUSSION
Intestinal human lactase is synthesized as a large precursor
(prepro-LPH) of 1927 amino acid residues which is subjected to
a number of proteolytic and other events before (and probably
also after) reaching the final destination, the brush-border
membrane. As prepared from this membrane, human LPH is a
glycoprotein with an apparent molecular mass (by SDS-PAGE)
of approximately 150–160 kDa, encompassing the amino acid
sequence from Ala869 to the COOH terminus (calculated mo-
lecular mass of the polypeptide chain, 120,993 Da). Mature
brush-border LPH corresponds, therefore, to the COOH-termi-
nal 56% of the original sequence of prepro-LPH. Although
number, types, and cellular sites of the proteolytic events pro-
ducing mature LPH from prepro-LPH have been studied ex-
tensively, albeit with controversial results, much less has been
learned about the proteases implicated in the maturation. A
central question in our investigation was whether PCs of the
furin type may partake in the series of events forming mature
LPH from human pro-LPH, as we have shown for the 180-kDa
intermediate occurring in the rabbit (23).
Processing of Prepro-LPH to Pro-LPH—To make sure that
the pro-LPH expressed in COS-7 cells had the same NH2 ter-
minus as pro-LPH formed in enterocytes, we have verified that
prepro-LPH is correctly converted to pro-LPH. Clearly (Fig.
1B), the signal peptidase in COS-7 ER splits prepro-LPH at the
site predicted for the human, i.e. after Gly19 (1) and found in
MDCK cells transfected with human prepro-LPH cDNA (4).
Hence, human pro-LPH expressed in COS-7 cells has the same
amino acid sequence as that expected in enterocytic pro-LPH.
The First Step of Processing Human Pro-LPH—Previous re-
ports from various laboratories, including ours, have indicated
that COS cells do not detectably process human pro-LPH (4, 23,
25, 39). In all of these studies fairly short chase times of a few
hours or less were used. We now find that long chase periods of
12–60 h do lead to substantial processing of pro-LPH to a
mature-like LPH by endogenous proteases of COS-7 cells. The
need for long chase periods can be attributed to a number of
reasons, alone or in combination: COS-7 cells may express PCs
in insufficient amounts to process the overexpressed amounts
of LPH rapidly, or the endogenous proteases have a subtly
different substrate specificity; COS-7 cell-specific glycosylation
may cause steric hindrance and/or subtly alter the structure of
pro-LPH segments otherwise susceptible to the action of PCs.
Because the mature-like LPH proteins obtained after extended
chase periods did not reveal unambiguous NH2-terminal se-
quences we have at least indirect evidence for the assumption
FIG. 3. NH2-terminal sequence analysis of the radiolabeled ma-
ture-like LPH produced in COS-7 cells cotransfected with furin.
Panel A, diagram of human LPH as predicted from the cDNA sequence
(1) and the amino acid sequence encompassing the last amino acid of
the pro domain (Arg868) and and the furin motif (Arg832) 36 amino acids
upstream. Panel B, COS-7 cells were transiently transfected with
cDNAs coding for human prepro-LPH and furin. They were metaboli-
cally labeled for 1 h in medium containing [3H]phenylalanine and then
chased for 10 h. The radioactive band corresponding to mature-like
LPH was excised and used directly for sequence determination. The
bars show the radioactivity released in each cycle. The predicted NH2-
terminal sequence of the mature-like 150-kDa LPH based on processing
at the COOH-terminal site of the R-T-P-R832 furin cleavage site is shown
below. * indicates the phenylalanine residues predicted to be radioactive
in the NH2-terminal sequence resulting from cleavage at Arg
832.
























that more than one type of protease is implicated in the proc-
essing of pro-LPH overexpressed in COS-7 cells. The relative
apparent homogeneity of the protein band (see Fig. 1A), how-
ever, strongly suggests that these cleavages occur within a
small segment of pro-LPH. From the data in Fig. 1A a precur-
sor/product relationship is not obvious; but this can be attrib-
uted to the short lived protein production in transient expres-
sion assays and the long chase periods.
The size of mature-like LPH formed in COS-7 and in MDCK
cells by endogenous proteases (24) is very similar to the size of
mature brush-border LPH, pointing to a proteolytic cleavage
taking place only very few kDa upstream of the NH2 terminus
of mature, brush-border LPH. In the cDNA-derived sequence of
prepro-LPH some motifs for furin-like PCs do occur at a short
distance from the native NH2 terminus, in particular one, 36
amino acids (or 4,034 Da) upstream of the native NH2 termi-
nus, R-T-P-R832. Overexpression of prepro-LPH together with
furin in COS-7 cells led to a 3-fold increase in the amount of
mature-like LPH produced by these cells. The addition of dec-
anoyl-Arg-Val-Lys-Arg-chloromethyl ketone, a reasonably
membrane-permeant furin inhibitor (29), to the medium inhib-
ited the enhanced processing of pro-LPH to mature-like LPH
(Fig. 2C). Adding BFA to the medium also blocked this proc-
essing, and furin is located both in the Golgi apparatus and at
the cell surface and translocates between these compartments
(34, 35). Finally, the site of this split in COS-7 cells cotrans-
fected with prepro-LPH and furin was identified unequivocally
by radioactive NH2-terminal sequence analysis of mature-like
LPH band using [3H]phenylalanine: the resulting sequence
X-X-X-F-F-X-X was in perfect agreement with the expected site
of processing by furin between positions 832 and 833, i.e. after
the motif R-T-P-R832 (Fig. 3). There can be little doubt, there-
fore, that this processing is indeed caused by furin.
Jacob et al. (24) also reported the occurrence of an interme-
diate in the processing of human pro-LPH in human small intes-
tinal biopsies or in transfected MDCK cells. Their intermediate is
also 3–4 kDa longer than mature LPH produced in vitro by the
addition of trypsin after biosynthesis. Contrary to these and our
own observations (previous paragraph), the same group (4) has,
however, also reported that a lactase form arises from cleavage
between positions Arg734 and Leu735 (not a furin motif) in MDCK
cells; this form is thus 134 amino acid residues longer (i.e. larger
by 15,132 Da) than mature, brush-border LPH, which makes it a
different and unlikely candidate as an intermediate in the proc-
essing of pro-LPH to mature LPH in enterocytes. It could perhaps
arise from the action of lysosomal proteases to which pro-LPH
FIG. 4. Processing of pro-LPH wt
and pro-LPH mutants. Panel A, loca-
tion of the mutations in the pro sequence:
(a) pro-LPH wt, (b) pro-LPH mutant
R829T/R832T, (c) pro-LPH mutant K853T/
R854T, (d) pro-LPH mutant K866T/
R868T. Panel B, analysis of endoproteo-
lytic processing of human pro-LPH wt
and pro-LPH mutant proteins in COS-7
cells. Cells were transfected with the cor-
responding cDNA of prepro-LPH wt (a)
and its mutants (b, c, and d) with or with-
out furin, labeled for 1 h, and chased for
6 h. (Only exposure of gels for shorter
times permits clear distinction of the two
bands at 210 and 220 kDa but does not
show the mature-like form any longer
(150 kDa).) Panel C, white bars, lactase
enzymatic activity of the different lacta-
ses: wt (a) and mutants (b, c, and d) ex-
pressed in COS-7 cells was compared with
lactase activity of untransfected cells (0).
Black bars, the activity of different LPH
forms cotransfected together with furin
cDNA. The results are the mean of three
independent experiments 6 S.E.
FIG. 5. Immunolocalization of pro-LPH wt and pro-LPH mutants in COS-7. Plasmids coding for prepro-LPH wt (A), R829T/R832T mutant
(B), K853T/R854T mutant (C), and K866T/R868T mutant (D) were introduced into COS-7 cells. 48 h after transfection the cells were fixed and
either permeabilized with Triton X-100 (1Tx) or not permeabilized (2Tx). The pro-LPHs were detected by indirect immunofluorescence using the
monoclonal antibody against mature human LPH. Bar 5 20 mm.
























expressed in COS-1 appears to be exposed (40).
The Double Mutant R829T/R832T of Human Pro-LPH Fails
to Reach the Plasma Membrane of COS-7 Cells—As discussed
above, furin, coexpressed with prepro-LPH in COS-7 cells,
splits pro-LPH at the sequence R-T-P-R832. We searched for
further confirmation of this conclusion by modifying this and
other consensus sequences by site-directed mutagenesis. Al-
though this experiment did not contribute to new conclusions,
it turned out to be interesting. Unexpectedly, the double mu-
tant R829T/R832T failed to appear in the plasma membranes
of these cells; it was retained in paranuclear bodies, tentatively
identified as ER (Fig. 5B). Thus, although no mature-like LPH
arose from this mutant, no conclusion could be drawn as to
whether the mutant was or was not susceptible to the action of
furin (which is located in later cell compartments). Probably
this mutant (and similar ones generated by others (24)) did not
acquire a conformation necessary to proceed past the ER. A
mechanism involving an abnormal conformation of the pro
sequence is appealing because it correlates with another obser-
vation: the pro sequence must be linked to the rest of LPH to
guarantee transport to the plasma membrane (25, 41): “pre-
LPH” (i.e. a lactase expressed with the signal peptide but
devoid of the pro segment) is retained in paranuclear or-
ganelles. The simultaneous formation of the pro domain and of
pre-LPH as separate individual proteins does not allow LPH to
exit from the ER, suggesting that the pro domain in its proper
context (and therefore properly folded) is essential for pro-LPH
transport to the plasma membrane.
It is known that proteins synthesized in the ER have to form
homo- or hetero-oligomers to move past this compartment (42,
43). The mechanism explaining why the pro domain in pro-
LPH is needed for pro-LPH to reach the plasma membrane is
not known, but oligomerization has been suggested (25, 41,
44–46). Alternatively, the pro domain might protect the lac-
tase proper from being cleaved by intracellular proteases before
reaching the plasma membrane. Whatever the mechanism, a
correctly folded pro region is needed, although some changes may
be tolerated (e.g. in the double mutants in Fig. 4, c and d, and Fig.
5, C and D). For some reason the double mutation R829T/R832T
interferes with this process (the lack of two positive charges
may impinge on the folding and/or on interactions).
Comparison of the four internal repeats I–IV in pro-LPH
reveals that furin-like motifs are present in mature LPH at
locations germane to Arg829 and Arg832, both in repeat III
(Arg1346 and Arg1349) and in repeat IV (Arg1822 and Lys1825),
i.e. in mature lactase. Whether this is of relevance or not is
unclear at this moment; at any rate, none of the “furin motifs”
in repeats III and IV seems to be attacked by any of the PCs,
although their sequences, R-T-A-R and R-I-P-K, would be in
principle susceptible to attack by furin-like PCs (47).
Summing Up—we have shown that pro-LPH arising from
prepro-LPH in COS-7 cells transfected with the corresponding
human cDNA has the same NH2 terminus expected in pro-LPH
from human enterocytes; that the proteolytic processing of this
pro-LPH is blocked by BFA (like the pro-LPH in cultures of
human small intestine (31), showing that this processing oc-
curs in the Golgi or in a later compartment (where a number of
proteases has been localized, including furin and furin-like
PCs); that COS-7 cells cotransfected with prepro-LPH and
furin cDNA process pro-LPH to a mature-like LPH, some 3–4
kDa larger than mature LPH; that this processing is inhibited by
a membrane-permeant furin inhibitor; and that this processing
takes place at position R-T-P-R832, which is one of the furin
sequences (47). This cleavage site is not far from but not identical
with that suggested by others (24) (who, incidentally, used a
somewhat different numbering). Although the work in the pres-
ent paper was carried out with transfected COS cells, our results
make it most likely that one or more of these PCs contribute to
the processing of human pro-LPH in the enterocytes in vivo,
because furin and furin-like PCs do occur in enterocytes (23).
The proteolytic processing of pro-LPH to LPH in man and in
the rabbit appears to involve in both species one or more
furin-like PCs. The most conspicuous difference is the apparent
size of the first intermediate, which is approximately 180 kDa
in the rabbit (23) but only 3–4 kDa larger than mature LPH in
man (mature-like LPH). The furin sequences cleaved in rabbit or
in the human pro-LPH are not the same. Rabbit pro-LPH is
cleaved at R-A-A-R349 in the second half of the homologous region
I (50); human pro-LPH does not have a furin motif here. Human
pro-LPH is split, instead, as shown here, to a far smaller first
intermediate, at the sequence R-T-P-R832, which occurs in the
rabbit also but is not utilized (50). (More furin sequences occur in
FIG. 6. Trypsin treatment of detergent extracts from COS-7
cells. Prepro-LPH was expressed in COS-7 cells with or without furin.
The cells were metabolically labeled for 1 h and chased for 7 h. Then cell
lysates were prepared, treated with 50 mg of trypsin for 5 min at 37 °C,
and immunoprecipitated with the monoclonal antibody against human
LPH. Each sample was divided into two equal aliquots, one of which
was treated with PNGase F.
FIG. 7. Schematic representation of the proteolytic processing
of human prepro-LPH. In the ER prepro-LPH is cleaved by signal
peptidase to generate pro-LPH, which is then cleaved in the trans-Golgi
network by a PC (furin or furin-like) to generate an intermediate
mature-like LPH. form The mature-like LPH is targeted to the brush-
border membrane (either directly or while undergoing additional pro-
teolytic cleavage(s) by endoproteases and/or aminopeptidases), in which
it is processed by pancreatic proteases (e.g. trypsin) to yield the final
mature LPH form. The numbers in parentheses refer to the NH2-termi-
nal amino acid number in the respective form.
























the pro sequences of pro-LPH, but a few only are utilized.)
How Is Mature, Brush-border LPH Ultimately Generated in
Vivo?—The NH2-terminal sequence in mature, brush-border
LPH is A-F-T-F-P . . . in man (38), A-S-A-L-P . . . in rabbit (1),
and V-T-D-S-L . . . in rat (48). As deduced from the cognate
cDNAs, these NH2-terminal sequences are preceded in pro-
LPH, by the amino acids P-S-K-V-R- (human (1)), P-S-K-T-R-
(rabbit (1)), and T-S-R-A-R- (rat (48)). An apparent consensus
motif (K/R-X-R-) immediately upstream of the NH2 terminus of
mature LPH could thus be made out. Wüthrich et al. (4) mu-
tated the Arg868 in human pro-LPH (which immediately pre-
cedes the NH2-terminal Ala
869 in mature, brush-border LPH)
to a Ile, Lys, or Glu; this had no effect on the proteolytic
processing of pro-LPH to mature (or rather mature-like) LPH
in transfected Caco-2 cells (as judged by SDS-PAGE). Similar
observations have been reported for another mutant also, in
which Arg868 was changed into a Thr and expressed in MDCK
cells (24). This mutant was not split by trypsin. Clearly, the
proteolytic processing that leads to mature, brush-border LPH
is more complicated than originally expected.
The events following the furin split after Arg832 and eventu-
ally removing the amino acids up to position 869 (the NH2
terminus of mature, brush-border LPH) are still poorly under-
stood. The most straightforward mechanism, as suggested,
e.g.., by Jacob et al. (24) for their intermediate is that trypsin
simply splits mature-like LPH after Arg868, thereby releasing a
36-amino acid long peptide. This mechanism would in fact be
very plausible and agrees with our observation that both in the
presence and absence of overexpressed furin cDNA human
mature-like pro-LPH is cleaved by trypsin to its final form.
However, the brush-border LPH from the enterocytes of (rat)
Thiry-Vella loops (which has never been exposed in vivo to
pancreatic proteases) is 2 amino acids longer than “regular” rat
LPH, i.e. has an NH2-terminal sequence A-R-V-T-D-S-L . . . ,
rather than V-T-D-S-L . . . (51). The enterocytes can, therefore,
almost (but not quite) produce mature, brush-border LPH in
the absence of trypsin. As mentioned in the previous para-
graph, the amino acid sequences immediately upstream of A-R-
V-T-D-S-L . . . are very homologous in rat rabbit and man. It
seems likely, therefore, that they are removed in the three
species by the same or similar proteases before the final trim-
ming of the last two amino acid residues by luminal trypsin. In
other words, it is most likely that the 34 amino acids between
Arg832 and Lys866 (see sequence a in fig. 4A) are removed as
small peptides and/or individually by enterocytic proteases,
possibly including granzyme A (52), brush-border aminopepti-
dases, and perhaps lysosomal cathepsins (Golgi resident pro-
teins have been shown to be exposed to cathepsins (49) and
(pro)lactase itself is likely to be exposed to lysosomal proteoly-
sis in COS-1 cells (40)).
In conclusion, human pro-LPH, far from being processed to
mature LPH in a single step, is subjected to a first intracellu-
lar, furin-like cut at position Arg832 and then to further cuts, by
enterocytic and (probably at the very end) by pancreatic pro-
teases (Fig. 7). The chain of events identified in the present
work provides therefore a more detailed picture to the concept,
already put forward earlier (see e.g. 53, 54), that in the proc-
essing of pro-LPH pancreatic proteases do play a role, but a
fairly limited one.
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